HCW Biologics enters exclusive distribution deal with Akron Biotech
HCW Biologics and Akron Biotech entered an exclusive distribution agreement for the commercialization of HCW11-006 as a reagent to produce highly functional human CAR-T cells, supported by pre-payment commitments.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day